CORMEDIX INC. Liabilities Assumed
CORMEDIX INC. (CRMD) reported Liabilities Assumed of $2.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2025-08-07
- CORMEDIX INC. liabilities assumed for the quarter ending 2024-12-31 was $0.00.
- CORMEDIX INC. liabilities assumed for the quarter ending 2024-09-30 was $0.00.
- CORMEDIX INC. liabilities assumed for the quarter ending 2024-06-30 was $0.00.
- CORMEDIX INC. liabilities assumed for the quarter ending 2024-03-31 was $2.00M.
- CORMEDIX INC. liabilities assumed for fiscal 2024 was $2.00M.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 6 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | $2.00M 10-K · filed 2025-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-08-07 | $2.00M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.00M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |